Post-Marketing Surveillance Services in India

What is Post-Marketing Surveillance? Definition and Strategic Importance

Post-Marketing Surveillance (PMS) refers to the systematic and ongoing monitoring of a product’s safety, effectiveness, and quality after it has been approved and introduced into the market.

Unlike pre-approval clinical trials, which are conducted in controlled environments with defined inclusion criteria, PMS captures real-world product use across diverse populations, including the elderly, children, and individuals with comorbidities.

PMS serves a dual purpose: it helps identify rare or long-term adverse events that may not emerge during clinical development, while also fulfilling regulatory obligations mandated by authorities such as the CDSCO, FDA, and EMA.

Strategically, effective PMS strengthens consumer confidence, optimizes the product’s benefit–risk profile, and supports evidence-based label updates and lifecycle management decisions.

India’s Evolving Pharmacovigilance Landscape and Regulatory Infrastructure

India has made strong progress in building a reliable and well-structured pharmacovigilance system over the last decade.

India now plays an important role in global post-marketing safety monitoring, reflecting a growing focus on patient safety and product quality across pharmaceuticals, nutraceuticals, medical devices, vaccines, and other regulated products.

The Pharmacovigilance Programme of India, coordinated by the Indian Pharmacopoeia Commission under the Ministry of Health and Family Welfare, manages the collection and evaluation of adverse event data through a nationwide network of reporting centres.

The Central Drugs Standard Control Organization (CDSCO) oversees regulatory compliance and safety reporting requirements.

India’s pharmacovigilance practices are increasingly aligned with international standards followed by agencies such as the US FDA and the EMA.

Improved reporting systems, digital platforms, and trained safety professionals have strengthened India’s regulatory infrastructure, making it a dependable and cost-effective environment for conducting post-marketing surveillance.

Pharmacovigilance Programme of India (PvPI) and Its Growing Global Impact

The Pharmacovigilance Programme of India (PvPI), managed by the Indian Pharmacopoeia Commission (IPC), was designated a WHO Collaborating Centre in 2017.

Since its inception, PvPI has seen remarkable growth, with over 113,000 Individual Case Safety Reports (ICSRs) collected by 2023, contributing to India’s 8th-place ranking globally in WHO VigiBase submissions (2025).

The program operates through 346+ Adverse Drug Reaction Monitoring Centres (AMCs) in hospitals and medical colleges, supported by four regional centers.

Spontaneous ADR reports are validated at AMCs, submitted via the SUGAM portal, and analyzed for regulatory action and signal detection, ensuring robust post-marketing safety oversight.

CDSCO Regulatory Mandates and Post-Marketing Obligations

Marketing Authorization Holders (MAHs) are responsible for the continuous monitoring of their products after approval, ensuring safety, quality, and effectiveness.

This includes submitting Periodic Safety Update Reports (PSURs) at defined intervals typically every six months for the first two years, and annually thereafter.

All PSURs must be filed through electronic reporting systems.

If any safety concerns are identified, regulatory authorities may take actions such as updating product labels, restricting use, or withdrawing the product, thereby safeguarding patient safety and maintaining regulatory compliance.

Types of Post-Marketing Surveillance Studies and Methodologies

Post-Marketing Surveillance (PMS) uses various study types to monitor the safety, effectiveness, and quality of products in real-world use.

Unlike controlled clinical trials, PMS captures data across diverse populations, long-term outcomes, and different usage patterns, helping identify rare adverse events, optimize benefit–risk profiles, and support regulatory and business decisions.

1. Spontaneous Reporting and Signal Detection
   Healthcare professionals, patients, or Marketing Authorization Holders (MAHs) report adverse events, which are validated, analyzed, and used to detect potential safety signals. Electronic portals like India’s SUGAM streamline reporting and regulatory review.
2. Observational Studies
   Cohort, case–control, and cross-sectional studies monitor product use without intervention, assessing long-term safety, rare events, and outcomes in diverse populations.
3. Phase IV Clinical Trials
   Post-approval trials evaluate safety or efficacy in larger or specialized populations, supporting label updates, new indications, or dosing adjustments.
4. Registries and Database Studies
   Patient registries and health records track outcomes and adverse events over time, offering insights into chronic conditions, rare diseases, or medical devices.
5. Risk Management and Periodic Reporting
   PMS involves preparing Periodic Safety Update Reports (PSURs) and implementing risk minimization strategies. Consolidated data support regulatory compliance, signal detection, and informed business decisions.

These methodologies together ensure continuous, comprehensive, and actionable insights into product safety and performance across its lifecycle.

Phase 4 Clinical Trials and Confirmatory Studies

Phase 4 clinical trials are post-marketing studies conducted after regulatory approval to evaluate long-term safety, efficacy, new indications, and comparative effectiveness.

In India, Fixed-Dose Combination (FDC) drugs with complex interactions require mandatory Phase 4 studies.

Common study designs include open-label observational trials, parallel comparisons with reference treatments, and long-term safety follow-ups.

These studies help optimize dosing, identify drug interactions, compare outcomes against standard therapies, and assess safety and effectiveness in special populations, ensuring ongoing patient protection and supporting regulatory compliance.

Spontaneous Adverse Event Reporting Systems and Pharmacovigilance

Spontaneous reporting allows healthcare professionals, patients, and manufacturers to voluntarily report adverse events to regulatory authorities.

Events are classified as Minor (no intervention), Moderate (therapy change or short hospitalization), Severe (life-threatening), or Lethal.

Reports follow global standards like CIOMS forms, MedDRA coding, and WHO-UMC assessment.

Collected data is analyzed to identify new or unexpected safety issues that may not have appeared during clinical trials, helping regulators and companies take timely action to protect patients.

Periodic Safety Update Reports (PSURs) and Benefit-Risk Assessment

PSURs provide a structured review of a product’s safety, including introduction, global authorization status, exposure data, clinical and non-clinical findings, post-market analysis, risk evaluation, and recommendations.

They are submitted every six months for the first two years and annually thereafter, with “NULL” reports if no adverse events occur.

PSURs summarize aggregate ADR data, causality assessments, and overall benefit-risk evaluations, guiding regulatory decisions such as label updates, prescribing information changes, and risk management plan adjustments to ensure ongoing product safety.

Signal Detection Methodologies and Data Mining Techniques

Signal detection uses statistical methods to identify potential safety issues from sources like adverse event reports, patient registries, electronic health records, and prescription monitoring.

Detected signals are confirmed, assessed for causality, and evaluated for risk to guide timely regulatory or safety actions.

Comprehensive Post-Marketing Surveillance Services

BioAgile Therapeutics provides end-to-end post-marketing surveillance (PMS) services to ensure the ongoing safety, efficacy, and compliance of pharmaceutical, nutraceutical, and medical device products.

Our services deliver real-world insights that protect patients, support regulatory requirements, and optimize the benefit-risk profile throughout the product lifecycle.

Phase 4 Clinical Trials

We conduct post-marketing studies to assess long-term safety, new indications, comparative effectiveness, and real-world outcomes.

Fixed-Dose Combination (FDC) drugs with complex interactions require mandatory Phase 4 studies in India.

Designs include open-label observational trials, parallel comparisons, and long-term follow-ups, helping optimize dosing, identify interactions, and assess special populations.

Spontaneous Adverse Event Reporting

We manage voluntary adverse event collection from healthcare professionals, patients, and manufacturers.

Events are classified, analyzed, and aggregated to detect new or unexpected safety signals, enabling timely regulatory action.

Periodic Safety Update Reports (PSURs)

Our team prepares structured PSURs covering global exposure, adverse events, and benefit-risk evaluation.

These reports inform label updates, prescribing information changes, and risk management strategies.

Signal Detection and Data Analysis

Using statistical methods and real-world data sources such as registries and electronic health records, we identify emerging safety concerns.

Signals are validated, assessed for causality, and evaluated for risk to support proactive regulatory and safety decisions.

BioAgile’s PMS services provide continuous monitoring, evidence-based risk management, and enhanced confidence in your products after launch.

Adverse Event Monitoring and Data Management

BioAgile provides end-to-end adverse event tracking, including report collection, validation, MedDRA coding, causality assessment, and submission via the SUGAM portal.

Serious or unexpected ADRs are reported within 15 days, while expected serious ADRs are submitted within 30 days, per CDSCO guidelines.

Our trained pharmacovigilance team ensures accurate classification, data consistency, source verification, and complete audit trails for regulatory compliance.

Pharmacovigilance Plan Development and Risk Management

BioAgile develops Risk Management Plans (RMPs) to proactively identify known and potential risks and define mitigation strategies.

This includes Risk Evaluation and Mitigation Strategies (REMS) such as restricted distribution programs, patient education, healthcare provider training, and label updates.

We prepare Safety Specifications to characterize identified or emerging risks and implement a monitoring plan combining routine surveillance and targeted studies to address safety gaps throughout the product lifecycle.

Phase 4 and Observational Study Conduct

BioAgile specializes in Phase 4 studies for Fixed-Dose Combination (FDC) drugs, ensuring compliance with regulatory requirements.

We conduct observational studies using non-randomized, open-label designs to capture real-world safety and effectiveness.

Patient registries are set up for prospective data collection across diverse populations.

Our services cover protocol development, site coordination, patient enrollment, data management, and regulatory reporting for seamless study execution.

Periodic Safety Update Report (PSUR) Preparation and Submission

BioAgile compiles PSURs by integrating global safety data from ICSRs, clinical trials, literature, and regulatory communications.

We conduct benefit-risk assessments, trend analyses, and evaluate emerging safety signals.

Reports are submitted via the SUGAM portal in eCTD format, ensuring organized documentation and compliance with regulatory timelines.

We also manage deficiency responses, providing comprehensive answers and supporting additional data requests from CDSCO.

Real-World Evidence Integration and Advanced Analytics

At BioAgile Therapeutics, we use real-world evidence (RWE) and advanced analytics to monitor the safety, effectiveness, and overall performance of products after launch.

We gather data from adverse event reports, patient registries, electronic health records, and clinical practice databases to understand how products perform in everyday use across diverse populations.

This approach allows us to identify emerging safety concerns, track trends, and evaluate benefit-risk profiles in real-world settings.

The insights support regulatory submissions, risk management plans, and label updates, helping ensure patient safety and compliance.

With expert pharmacovigilance oversight and structured data analysis, BioAgile delivers actionable insights that enable companies to make informed decisions, protect patients, and maintain confidence in their products.

Patient Registries and Observational Data Collection

BioAgile uses patient registries to collect standardized, non-interventional data from routine clinical practice.

Registries capture patient demographics, clinical characteristics, comorbidities, medication use, outcomes, and quality of life.

They include real-world populations such as the elderly, children, pregnant women, and patients with multiple conditions who are often underrepresented in clinical trials.

This approach allows longer follow-up, larger patient numbers, diverse healthcare settings, and flexible treatment monitoring, providing insights that reflect how products perform in everyday practice.

India-Specific PMS Regulatory Requirements and Compliance

In India, Post-Marketing Surveillance (PMS) is regulated to ensure the ongoing safety, efficacy, and quality of pharmaceutical, nutraceutical, and medical device products.

The Central Drugs Standard Control Organization (CDSCO) and the Pharmacovigilance Programme of India (PvPI) provide the framework for adverse event reporting, risk management, and compliance monitoring.

Marketing Authorization Holders (MAHs) are responsible for continuous product oversight, including the collection, validation, and reporting of adverse events.

They must submit Periodic Safety Update Reports (PSURs) every six months for the first two years after approval and annually thereafter.

Even if no adverse events occur, “NULL” reports are required to maintain compliance.

Serious or unexpected adverse events must be reported promptly, while expected serious events follow standard reporting timelines.

India also mandates materiovigilance for medical devices, requiring adverse event reporting through a network of Medical Device Monitoring Centres (MDMCs).

Regulatory authorities may take action if safety concerns arise, including label changes, restricted use, or product withdrawal.

BioAgile supports companies in meeting India-specific PMS requirements, including PSUR preparation, adverse event tracking, risk management, and regulatory submissions.

Our services help ensure compliance with CDSCO and PvPI regulations, safeguard patient safety, and maintain confidence in your products throughout their lifecycle.

CDSCO SUGAM Portal and eCTD Submission Requirements

The SUGAM portal is India’s mandatory electronic gateway for CDSCO submissions, including PSUR filings (effective 2024).

All submissions must follow eCTD standards, ensuring proper document organization and metadata.

BioAgile manages submission timelines, regulatory review periods, and deficiency responses, helping companies stay compliant.

We also provide guidance on portal rules, validation checks, and rejection reasons, ensuring accurate and efficient electronic submissions to regulatory authorities.

FDC Phase 4 Compliance and Study Timelines

In India, all Fixed-Dose Combination (FDC) drugs approved after specific dates require mandatory Phase 4 studies.

These studies typically run 12–24 months post-approval and include diverse patient populations.

BioAgile integrates clinical efficacy and real-world safety data while assessing pharmacokinetics, drug interactions, and special populations.

This ensures compliance with regulatory expectations and provides a complete understanding of product performance in real-world settings.

Pharmacovigilance Training and Compliance Documentation

MAHs must maintain a trained pharmacovigilance team and comply with Good Pharmacovigilance Practices (GVP).

BioAgile supports SOP creation, adverse event tracking, and personnel qualification documentation.

We also provide training programs on regulatory updates and signal detection.

We ensure audit readiness, including CDSCO inspection preparation and secure archival of records for at least five years.

Signal Detection, Causality Assessment, and Regulatory Actions

At BioAgile Therapeutics, we monitor product safety through signal detection, identifying potential safety concerns from adverse event reports, patient registries, electronic health records, and prescription data.

Early detection allows for timely investigation and risk management.

Detected signals undergo causality assessment to determine the likelihood that the event is related to the product.

Events are classified by severity minor, moderate, severe, or lethal to prioritize actions and protect patients.

Based on these assessments, we support regulatory reporting and risk management, helping companies implement measures such as label updates, prescribing information changes, restricted use, or product withdrawal when required.

All analyses are conducted in line with CDSCO, PvPI, and international pharmacovigilance standards.

By combining signal detection, causality assessment, and regulatory actions, BioAgile ensures continuous post-marketing safety monitoring, supports compliance, and provides actionable insights for patient protection and informed product management.

ADR Signal Generation and Causality Assessment Process

An ADR signal is information suggesting a possible link between a product and an adverse event.

At BioAgile, signals are assessed using WHO-UMC causality categories—Certain, Probable/Likely, Possible, Unlikely, Conditional, and Unclassifiable.

Evaluation considers the temporal relationship between drug administration and the event, ensuring timing is appropriate for a potential drug effect.

Dechallenge and rechallenge data, observing improvement after stopping the drug and recurrence upon reintroduction, further strengthen causality.

This structured approach ensures accurate classification and supports informed regulatory and safety decisions.

Risk Evaluation and Regulatory Decision-Making

BioAgile evaluates risks by considering their frequency, severity, and affected populations.

We assess the benefit-risk balance, weighing therapeutic benefits against potential safety concerns for specific patients.

When risks outweigh benefits, appropriate regulatory actions are taken, such as label updates, Risk Evaluation and Mitigation Strategies (REMS), or product withdrawal.

A clear communication plan ensures healthcare providers, patients, and the public are informed about identified risks and the measures in place to manage them.

Competitive Advantages of India for PMS Services

India offers unique advantages for Post-Marketing Surveillance (PMS) due to its diverse population, covering varied ages, genetics, comorbidities, and medication use, providing rich real-world data.

Conducting Phase 4 and observational studies in India is also cost-effective, often significantly lower than in Western markets, while maintaining high-quality standards.

The country has strong regulatory expertise, with CDSCO-regulated facilities, skilled pharmacovigilance professionals, and a well-established network of 346+ Adverse Drug Reaction Monitoring Centres (AMCs).

Advanced infrastructure, including patient registries and integrated data management systems, enables rapid patient enrollment, thorough monitoring, and reliable data collection.

India’s capabilities are recognized globally, ranking 8th in WHO pharmacovigilance contributions, reflecting world-class expertise trusted by international stakeholders.

These factors make India a preferred destination for PMS services, combining quality, efficiency, and comprehensive real-world insights for regulatory compliance and patient safety.

Why Choose BioAgile Therapeutics for Post-Marketing Surveillance Services

BioAgile Therapeutics offers integrated PMS expertise under one roof, combining clinical research, pharmacovigilance, regulatory affairs, and data analytics.

Our team has established relationships with CDSCO, enabling smooth regulatory consultations and pre-submission guidance for faster approvals.

With a proven track record, we have successfully conducted Phase 4 studies, prepared PSURs, and delivered actionable signal detection outcomes across multiple therapeutic areas.

Our operations emphasize quality and efficiency, including timely SUGAM portal submissions, rigorous data management, and prompt resolution of regulatory deficiencies.

Our comprehensive services are designed to maximize sponsor ROI through efficient study design, patient enrollment, and regulatory compliance.

Choosing BioAgile ensures end-to-end post-marketing safety monitoring, expert regulatory support, and actionable insights, helping you maintain product safety, patient trust, and compliance in a cost-effective manner.

Frequently Asked Questions